ALK has a long tradition of research activities within recombinant allergens. Recombinant allergens are produced using sophisticated genetic engineering, and they will allow production of future vaccines independent of access to natural allergen sources.
With more than 20 years of experience as pioneers in the field of recombinant allergens, ALK's researchers were the first to characterize and describe the structures of the most important inhalation allergens from birch pollen and house dust mites.
The company manages a large portfolio of patents and intellectual property rights which ensures the necessary freedom to use relevant recombinant allergens in its commercial products.